Read our latest updates & insights

Mylan and Biocon announced the launch of Ogivri® in the US. This FDA-approved product was co-developed by Biocon Biologics and Mylan.

Amneal and Amgen settle patent dispute over filgrastim biosimilar. Notice of the settlement was approved by a US Federal Court, however no further details have been published. Amgen had filed the complaint against Amneal in March 2018, alleging infringement of a number of p...

Coherus and Amgen settle suit over adalimumab. Notice of the agreement has been approved by a US Federal Court, however no further details about the settlement have been published. This dispute arose when Amgen launched Amgevita® in Europe in 2018 (manufactured in the US), ...

Biocon announces its supplemental BLA (sBLA) for biosimilar pegfilgrastim has been approved by the FDA. This additional approval relates to FDA approval of Biocon’s subsidiary Biocon Biologics’ new manufacturing facility in Bengalaru.

Shanghai Henlius announces proposed trastuzumab biosimilar met primary endpoint in Phase III clinical trials.

Coherus and Bioeq announce licensing agreement for Lucentis® (ranibizumab) in the US. Under the agreement, Bioeq will receive upfront and launch milestone payments, with both parties sharing the profits.

Pfizer receives Australian approval for bevacizumab biosimilar, Zirabev®.

FDA accepts BLA for proposed bevacizumab biosimilar.

Polpharma commences dosing in Phase III trials of proposed natalizumab biosimilar.

Sandoz launches pegfilgrastim product, Ziextenzo®, in the US, at a 37% discount to the reference product, Neulasta®.